TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 6 MedPage Today opinion piece argues that Democratic gains in the 2026 midterms could create opportunities to pursue health policy changes in 2027 and 2028. The author says the party could face obstacles including presidential vetoes, Senate procedures, funding constraints and battles over federal health agency leadership.
Steven Grossman, writing in a November 6 MedPage Today opinion article, says Democratic gains in the November 3, 2026, midterms could give the party an opening to pursue health policy priorities in the next Congress, but warns that delivering changes will be difficult. He points to potential fights over Medicaid, Affordable Care Act premium subsidies and federal health agency leadership, while stressing that presidential vetoes, funding limits and congressional procedures could constrain action.
Grossman, a lawyer and health policy commentator, argues that healthcare grievances contributed to voters’ dissatisfaction with the administration. He describes the election as a political turning point and says Democrats will need to produce concrete results during the next two years if they want to retain voter support. Those are the author’s assessments; the source article does not provide election results by district or voting data that would establish the scale of a Democratic majority or the role healthcare played in individual votes.
The article anticipates limited health policy action during the lame-duck session between the election and the new Congress’s scheduled start on January 3, 2027. Grossman says legislation and nominations often stall during this period without broad bipartisan backing or a strong sense of urgency. He expects the session to focus mainly on government funding and other major outstanding business, rather than new healthcare measures.
For 2027 and 2028, Grossman identifies several possible points of conflict. He predicts Democratic-led investigations of the administration’s vaccine policies, with measles a likely early focus, and says Democrats could pursue legislation, attach provisions to must-pass bills or seek negotiated compromises. He also identifies a possible effort to reverse Medicaid cuts and restore ACA premium subsidies, but says financing would be a major obstacle. The article estimates that those ambitions would require $1.2 trillion over 10 years; it does not detail a final legislative proposal or how that sum would be raised.
The Funding Test for Health Priorities
The article matters because it maps how a change in congressional control could affect federal health policy, while making clear that electoral gains do not automatically translate into enacted laws. If Democrats pursue changes to Medicaid or ACA subsidies, the effects would depend on the scope of any legislation, its financing, Senate rules and the president’s response. Grossman notes that President Donald Trump could veto bills, leaving lawmakers to consider whether to negotiate or use legislative vehicles that require fewer votes.
The practical stakes extend beyond party strategy. Medicaid policy affects coverage for eligible people and the budgets of states and health providers; ACA subsidies influence premiums for people buying insurance through the marketplaces. But the source does not specify which provisions would be changed, who would qualify under any proposed policy, or what the cost to households or government would be. Those details would require legislation and fiscal estimates that are not yet available in the article.
Health agency leadership is another consequential issue. Grossman anticipates scrutiny of Health and Human Services Secretary Robert F. Kennedy Jr. and a difficult path for FDA commissioner nominee Heidi Overton. These are forecasts by the author, not announcements that Kennedy will leave or that Overton’s nomination has been rejected.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Garmin Venu 4 GPS Smartwatch, 45 mm AMOLED, Slate/Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
The Congressional Calendar Ahead
The election took place on November 3, 2026, according to the article, and the next Congress is scheduled to begin on January 3, 2027. The interval before that date is the lame-duck period, when the outgoing Congress remains in session. Grossman says members who are retiring or have lost their races may have little incentive to take up contested legislation, and procedural or timing barriers can further limit what is completed.
Grossman also points to the coming reauthorization of FDA user fee legislation, which must be enacted by September 30, 2027, according to his account. Such bills can carry provisions beyond their central purpose. He suggests Democrats may seek to attach the Clinical Trial Modernization Act or other policy measures, with June or July a preferred target for completion. The source describes this as a possible strategy, not a settled Democratic plan.
On nominations, Grossman says nominations that have not been confirmed expire when the new Congress convenes, requiring the White House to submit names again if it wants to proceed. He argues Overton would face especially difficult confirmation prospects, but the article does not report a Senate vote or a formal withdrawal of her nomination.
“Democrats must deliver.”
— Steven Grossman, in MedPage Today
Plans, Votes and Costs Remain Open
The source is an opinion article offering predictions, not a report of enacted policy or a confirmed Democratic agenda. It does not establish the final composition or leadership of the incoming Congress, identify specific bills that Democrats have committed to introduce, or provide a detailed plan for paying for the proposed health priorities.
It is also unclear whether Kennedy will remain HHS secretary, whether Overton will be nominated again, and what steps the White House or Senate will take on FDA leadership. Grossman predicts that Kennedy could resign under congressional pressure and that Overton’s confirmation prospects are poor, but neither outcome is presented as confirmed. The article likewise does not establish whether an investigation into vaccine policy will begin or what evidence any hearings would examine.
The timing and content of any compromise with Trump are also uncertain. The administration could veto legislation, but the article does not say whether negotiations will occur or which proposals might attract bipartisan support. Any estimate of policy effects would depend on the specific bills ultimately drafted and passed.
The First Tests in 2027
The first near-term milestone is the outgoing Congress’s lame-duck session, followed by the new Congress’s scheduled opening on January 3, 2027. Readers can then watch for committee leadership, hearing schedules, renewed nominations and the introduction of health policy bills. These developments would show whether the priorities Grossman identifies become formal party proposals.
Later in 2027, Congress will face the deadline for renewing FDA user fee legislation by September 30. Any attempt to add other health measures to that bill would need to emerge through the legislative process; Grossman’s suggested Clinical Trial Modernization Act rider remains a forecast. Medicaid and ACA subsidy proposals would also need funding plans and sufficient votes, and could face a presidential veto.
The article’s analysis therefore describes a possible agenda, not a guaranteed legislative outcome. The next clear evidence will come from congressional actions, White House decisions and the text and financing of any bills introduced.
Key Questions
What is the news development?
Steven Grossman published an opinion article on November 6, 2026, outlining health policy challenges and possible Democratic strategies after the November 3 midterm elections.
Have Democrats announced a plan to restore ACA subsidies or reverse Medicaid cuts?
The source does not report a finalized Democratic plan. Grossman identifies those policies as potential priorities and says financing them would be a substantial challenge.
Is Robert F. Kennedy Jr. leaving his position?
No departure is confirmed in the source. Grossman predicts Kennedy may resign amid congressional scrutiny, but presents this as his expectation rather than an announced decision.
What could happen to the FDA commissioner nomination?
Grossman argues that Heidi Overton’s nomination faces poor confirmation prospects, particularly in a Senate led by Democrats. The article does not report a confirmation vote, rejection or withdrawal.
When could the next major health policy decisions occur?
The new Congress is scheduled to begin on January 3, 2027. Grossman also points to FDA user fee legislation due by September 30, 2027, as a possible vehicle for other health measures.
Source: medpagetoday.com
